JP2008530011A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008530011A5 JP2008530011A5 JP2007554205A JP2007554205A JP2008530011A5 JP 2008530011 A5 JP2008530011 A5 JP 2008530011A5 JP 2007554205 A JP2007554205 A JP 2007554205A JP 2007554205 A JP2007554205 A JP 2007554205A JP 2008530011 A5 JP2008530011 A5 JP 2008530011A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- pyridin
- pyrazol
- alkyl
- oxime
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims 77
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims 63
- 125000000623 heterocyclic group Chemical group 0.000 claims 49
- 125000000217 alkyl group Chemical group 0.000 claims 45
- 125000003118 aryl group Chemical group 0.000 claims 32
- -1 carbocycle Chemical group 0.000 claims 30
- 125000004452 carbocyclyl group Chemical group 0.000 claims 27
- 125000003342 alkenyl group Chemical group 0.000 claims 18
- 125000000304 alkynyl group Chemical group 0.000 claims 16
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 claims 13
- 125000004649 C2-C8 alkynyl group Chemical group 0.000 claims 13
- 229910052739 hydrogen Inorganic materials 0.000 claims 13
- 239000000203 mixture Substances 0.000 claims 13
- 206010028980 Neoplasm Diseases 0.000 claims 11
- 125000004429 atom Chemical group 0.000 claims 11
- 201000011510 cancer Diseases 0.000 claims 10
- 229910052760 oxygen Inorganic materials 0.000 claims 10
- 229910052799 carbon Inorganic materials 0.000 claims 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 8
- 125000005842 heteroatom Chemical group 0.000 claims 8
- 229910052757 nitrogen Inorganic materials 0.000 claims 8
- 150000003951 lactams Chemical class 0.000 claims 7
- 150000002596 lactones Chemical class 0.000 claims 7
- 238000000034 method Methods 0.000 claims 7
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 7
- SNOOUWRIMMFWNE-UHFFFAOYSA-M sodium;6-[(3,4,5-trimethoxybenzoyl)amino]hexanoate Chemical compound [Na+].COC1=CC(C(=O)NCCCCCC([O-])=O)=CC(OC)=C1OC SNOOUWRIMMFWNE-UHFFFAOYSA-M 0.000 claims 7
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 6
- 239000003814 drug Substances 0.000 claims 6
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 6
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 5
- 238000004519 manufacturing process Methods 0.000 claims 5
- 229910052717 sulfur Inorganic materials 0.000 claims 5
- 229940124597 therapeutic agent Drugs 0.000 claims 5
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims 4
- 208000024172 Cardiovascular disease Diseases 0.000 claims 4
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 208000035475 disorder Diseases 0.000 claims 4
- 230000000069 prophylactic effect Effects 0.000 claims 4
- 125000006239 protecting group Chemical group 0.000 claims 4
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims 4
- 238000002560 therapeutic procedure Methods 0.000 claims 4
- GBXQPDCOMJJCMJ-UHFFFAOYSA-M trimethyl-[6-(trimethylazaniumyl)hexyl]azanium;bromide Chemical compound [Br-].C[N+](C)(C)CCCCCC[N+](C)(C)C GBXQPDCOMJJCMJ-UHFFFAOYSA-M 0.000 claims 4
- 241000124008 Mammalia Species 0.000 claims 3
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 claims 3
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 claims 3
- 230000004770 neurodegeneration Effects 0.000 claims 3
- 208000015122 neurodegenerative disease Diseases 0.000 claims 3
- 125000004193 piperazinyl group Chemical group 0.000 claims 3
- 125000004076 pyridyl group Chemical group 0.000 claims 3
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 3
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims 3
- 125000005942 tetrahydropyridyl group Chemical group 0.000 claims 3
- 125000001544 thienyl group Chemical group 0.000 claims 3
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims 2
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims 2
- KDDQRKBRJSGMQE-UHFFFAOYSA-N 4-thiazolyl Chemical group [C]1=CSC=N1 KDDQRKBRJSGMQE-UHFFFAOYSA-N 0.000 claims 2
- CWDWFSXUQODZGW-UHFFFAOYSA-N 5-thiazolyl Chemical group [C]1=CN=CS1 CWDWFSXUQODZGW-UHFFFAOYSA-N 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 201000001320 Atherosclerosis Diseases 0.000 claims 2
- JQGPBDSMTHZOMO-UHFFFAOYSA-N OBO.C=1C=NNC=1 Chemical class OBO.C=1C=NNC=1 JQGPBDSMTHZOMO-UHFFFAOYSA-N 0.000 claims 2
- 201000004681 Psoriasis Diseases 0.000 claims 2
- 208000015634 Rectal Neoplasms Diseases 0.000 claims 2
- 235000010290 biphenyl Nutrition 0.000 claims 2
- 239000004305 biphenyl Substances 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 125000005057 dihydrothienyl group Chemical group S1C(CC=C1)* 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 125000002883 imidazolyl group Chemical group 0.000 claims 2
- 208000027866 inflammatory disease Diseases 0.000 claims 2
- 125000000842 isoxazolyl group Chemical group 0.000 claims 2
- 208000019423 liver disease Diseases 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 210000000214 mouth Anatomy 0.000 claims 2
- 125000001624 naphthyl group Chemical group 0.000 claims 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 2
- 125000002971 oxazolyl group Chemical group 0.000 claims 2
- 125000003226 pyrazolyl group Chemical group 0.000 claims 2
- 206010038038 rectal cancer Diseases 0.000 claims 2
- 201000001275 rectum cancer Diseases 0.000 claims 2
- 208000037803 restenosis Diseases 0.000 claims 2
- 125000000335 thiazolyl group Chemical group 0.000 claims 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 2
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 claims 1
- IZQZVLNYVZCOPX-UHFFFAOYSA-N 2-[2-[4-(1-hydroxyimino-2,3-dihydroinden-5-yl)-3-pyridin-4-ylpyrazol-1-yl]ethylamino]ethanol Chemical compound N=1N(CCNCCO)C=C(C=2C=C3CCC(C3=CC=2)=NO)C=1C1=CC=NC=C1 IZQZVLNYVZCOPX-UHFFFAOYSA-N 0.000 claims 1
- FKWQBUGNQFJRGV-UHFFFAOYSA-N 2-[4-(1,3-benzodioxol-5-yl)-3-pyridin-4-ylpyrazol-1-yl]ethanol Chemical compound N=1N(CCO)C=C(C=2C=C3OCOC3=CC=2)C=1C1=CC=NC=C1 FKWQBUGNQFJRGV-UHFFFAOYSA-N 0.000 claims 1
- MJESHTQDIHRJJJ-UHFFFAOYSA-N 2-[4-(1-amino-2,3-dihydro-1h-inden-5-yl)-3-pyridin-4-ylpyrazol-1-yl]ethanol Chemical compound C=1C=C2C(N)CCC2=CC=1C1=CN(CCO)N=C1C1=CC=NC=C1 MJESHTQDIHRJJJ-UHFFFAOYSA-N 0.000 claims 1
- IEPBUTPKELRFKK-UHFFFAOYSA-N 2-[4-(1-amino-2,3-dihydro-1h-inden-5-yl)-5-pyridin-4-ylpyrazol-1-yl]ethanol Chemical compound C=1C=C2C(N)CCC2=CC=1C=1C=NN(CCO)C=1C1=CC=NC=C1 IEPBUTPKELRFKK-UHFFFAOYSA-N 0.000 claims 1
- PKGNJPQGDHTVGY-UHFFFAOYSA-N 2-[4-(1-hydroxyimino-2,3-dihydroinden-5-yl)-3-pyridin-4-ylpyrazol-1-yl]pyridine-3-carbonitrile Chemical compound C=1C=C2C(=NO)CCC2=CC=1C1=CN(C=2C(=CC=CN=2)C#N)N=C1C1=CC=NC=C1 PKGNJPQGDHTVGY-UHFFFAOYSA-N 0.000 claims 1
- SQFQKKPNPXONBG-UHFFFAOYSA-N 2-[4-(1-hydroxyimino-2,3-dihydroinden-5-yl)-5-pyridin-4-ylpyrazol-1-yl]ethanol Chemical compound OCCN1N=CC(C=2C=C3CCC(C3=CC=2)=NO)=C1C1=CC=NC=C1 SQFQKKPNPXONBG-UHFFFAOYSA-N 0.000 claims 1
- JWAZRIHNYRIHIV-UHFFFAOYSA-N 2-naphthol Chemical compound C1=CC=CC2=CC(O)=CC=C21 JWAZRIHNYRIHIV-UHFFFAOYSA-N 0.000 claims 1
- VATRAMGKPXJFAV-UHFFFAOYSA-N 3-[4-(1-hydroxyimino-2,3-dihydroinden-5-yl)-3-pyridin-4-ylpyrazol-1-yl]propane-1,2-diol Chemical compound N=1N(CC(O)CO)C=C(C=2C=C3CCC(C3=CC=2)=NO)C=1C1=CC=NC=C1 VATRAMGKPXJFAV-UHFFFAOYSA-N 0.000 claims 1
- RCBZCSONTXNSHW-UHFFFAOYSA-N 4-[1-piperidin-4-yl-4-[6-(1h-pyrazol-5-yl)-2,4,5,6-tetrahydro-1h-inden-5-yl]pyrazol-3-yl]pyridine Chemical compound C1C2=CCCC2=CC(C2=NNC=C2)C1C1=CN(C2CCNCC2)N=C1C1=CC=NC=C1 RCBZCSONTXNSHW-UHFFFAOYSA-N 0.000 claims 1
- 125000001054 5 membered carbocyclic group Chemical group 0.000 claims 1
- RICPRHNLFHUQIT-UHFFFAOYSA-N 5-(1-methyl-3-pyridin-4-ylpyrazol-4-yl)-1,3-dihydroindol-2-one Chemical compound N=1N(C)C=C(C=2C=C3CC(=O)NC3=CC=2)C=1C1=CC=NC=C1 RICPRHNLFHUQIT-UHFFFAOYSA-N 0.000 claims 1
- NWAIAPGJHCMCJQ-UHFFFAOYSA-N 5-(1-methyl-3-pyridin-4-ylpyrazol-4-yl)-2,3-dihydroinden-1-one Chemical compound N=1N(C)C=C(C=2C=C3CCC(=O)C3=CC=2)C=1C1=CC=NC=C1 NWAIAPGJHCMCJQ-UHFFFAOYSA-N 0.000 claims 1
- XIWGEASMKDCYFJ-UHFFFAOYSA-N 5-(5-pyridin-4-yl-1h-pyrazol-4-yl)-2,3-dihydroinden-1-one Chemical compound C=1C=C2C(=O)CCC2=CC=1C1=CNN=C1C1=CC=NC=C1 XIWGEASMKDCYFJ-UHFFFAOYSA-N 0.000 claims 1
- CACKWIAQZGWUDK-UHFFFAOYSA-N 5-[1-(1-methylpiperidin-4-yl)-3-pyridin-4-ylpyrazol-4-yl]-3h-isoindol-1-amine Chemical compound C1CN(C)CCC1N1N=C(C=2C=CN=CC=2)C(C=2C=C3CNC(=N)C3=CC=2)=C1 CACKWIAQZGWUDK-UHFFFAOYSA-N 0.000 claims 1
- DEZZLWQELQORIU-UHFFFAOYSA-N 5-[1-(2-hydroxyethyl)-3-pyridin-4-yl-4-pyrazolyl]-2,3-dihydroinden-1-one oxime Chemical compound N=1N(CCO)C=C(C=2C=C3CCC(C3=CC=2)=NO)C=1C1=CC=NC=C1 DEZZLWQELQORIU-UHFFFAOYSA-N 0.000 claims 1
- MGGQMXLSPADSGN-UHFFFAOYSA-N 5-[1-(2-hydroxyethyl)-3-pyridin-4-ylpyrazol-4-yl]-1,3-dihydroindol-2-one Chemical compound N=1N(CCO)C=C(C=2C=C3CC(=O)NC3=CC=2)C=1C1=CC=NC=C1 MGGQMXLSPADSGN-UHFFFAOYSA-N 0.000 claims 1
- UMUDEJRSKACPSS-UHFFFAOYSA-N 5-[1-(2-hydroxyethyl)-3-pyridin-4-ylpyrazol-4-yl]-1h-quinazolin-4-one Chemical compound N=1N(CCO)C=C(C=2C=3C(=O)NC=NC=3C=CC=2)C=1C1=CC=NC=C1 UMUDEJRSKACPSS-UHFFFAOYSA-N 0.000 claims 1
- XRDGWIKOQYEFOL-UHFFFAOYSA-N 5-[1-(2-hydroxyethyl)-3-pyridin-4-ylpyrazol-4-yl]-2,3-dihydroinden-1-one Chemical compound N=1N(CCO)C=C(C=2C=C3CCC(=O)C3=CC=2)C=1C1=CC=NC=C1 XRDGWIKOQYEFOL-UHFFFAOYSA-N 0.000 claims 1
- UIBKJNFSKLXWTK-UHFFFAOYSA-N 5-[1-(2-hydroxyethyl)-3-pyridin-4-ylpyrazol-4-yl]-2,3-dihydrophthalazine-1,4-dione Chemical compound N=1N(CCO)C=C(C=2C3=C(C(NNC3=O)=O)C=CC=2)C=1C1=CC=NC=C1 UIBKJNFSKLXWTK-UHFFFAOYSA-N 0.000 claims 1
- VFWDUSGVXPKDHF-UHFFFAOYSA-N 5-[1-(2-hydroxyethyl)-3-pyridin-4-ylpyrazol-4-yl]-2-(2-methoxyethyl)isoindole-1,3-dione Chemical compound C1=C2C(=O)N(CCOC)C(=O)C2=CC=C1C1=CN(CCO)N=C1C1=CC=NC=C1 VFWDUSGVXPKDHF-UHFFFAOYSA-N 0.000 claims 1
- YNEHWTFXTODKTQ-UHFFFAOYSA-N 5-[1-(2-hydroxyethyl)-3-pyridin-4-ylpyrazol-4-yl]-2h-isoquinolin-1-one Chemical compound N=1N(CCO)C=C(C=2C3=CC=NC(O)=C3C=CC=2)C=1C1=CC=NC=C1 YNEHWTFXTODKTQ-UHFFFAOYSA-N 0.000 claims 1
- SZOSXNZCMNUXFR-UHFFFAOYSA-N 5-[1-[2-(4-methylpiperazin-1-yl)ethyl]-3-pyridin-4-ylpyrazol-4-yl]-2,3-dihydro-1h-inden-1-amine Chemical compound C1CN(C)CCN1CCN1N=C(C=2C=CN=CC=2)C(C=2C=C3CCC(N)C3=CC=2)=C1 SZOSXNZCMNUXFR-UHFFFAOYSA-N 0.000 claims 1
- 125000004008 6 membered carbocyclic group Chemical group 0.000 claims 1
- HXGBUKKPDSRQTR-UHFFFAOYSA-N 6-(1-methyl-3-pyridin-4-ylpyrazol-4-yl)naphthalen-1-ol Chemical compound N=1N(C)C=C(C=2C=C3C=CC=C(O)C3=CC=2)C=1C1=CC=NC=C1 HXGBUKKPDSRQTR-UHFFFAOYSA-N 0.000 claims 1
- RILYHIWSBNWFIQ-GMAHTHKFSA-N 6-[1-[(1s,2s)-2-hydroxycyclohexyl]-3-pyridin-4-ylpyrazol-4-yl]naphthalen-1-ol Chemical compound O[C@H]1CCCC[C@@H]1N1N=C(C=2C=CN=CC=2)C(C=2C=C3C=CC=C(O)C3=CC=2)=C1 RILYHIWSBNWFIQ-GMAHTHKFSA-N 0.000 claims 1
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 claims 1
- 208000003200 Adenoma Diseases 0.000 claims 1
- 206010001233 Adenoma benign Diseases 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 208000019838 Blood disease Diseases 0.000 claims 1
- 206010005949 Bone cancer Diseases 0.000 claims 1
- 208000020084 Bone disease Diseases 0.000 claims 1
- 208000018084 Bone neoplasm Diseases 0.000 claims 1
- 201000006474 Brain Ischemia Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 201000009030 Carcinoma Diseases 0.000 claims 1
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 1
- 208000006029 Cardiomegaly Diseases 0.000 claims 1
- 206010008120 Cerebral ischaemia Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 201000003883 Cystic fibrosis Diseases 0.000 claims 1
- 206010012442 Dermatitis contact Diseases 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 206010019280 Heart failures Diseases 0.000 claims 1
- 208000017604 Hodgkin disease Diseases 0.000 claims 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 206010020880 Hypertrophy Diseases 0.000 claims 1
- 206010021143 Hypoxia Diseases 0.000 claims 1
- 208000029462 Immunodeficiency disease Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims 1
- 206010023825 Laryngeal cancer Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- RMTGMEXYMKRUSY-UHFFFAOYSA-N N-[5-(1-methyl-5-pyridin-4-ylpyrazol-4-yl)-2,3-dihydroinden-1-ylidene]hydroxylamine Chemical compound CN1N=CC(C=2C=C3CCC(C3=CC=2)=NO)=C1C1=CC=NC=C1 RMTGMEXYMKRUSY-UHFFFAOYSA-N 0.000 claims 1
- HNYYFWGWLSEHQF-UHFFFAOYSA-N N-[5-(5-pyridin-4-yl-1H-pyrazol-4-yl)-2,3-dihydroinden-1-ylidene]hydroxylamine Chemical compound C=1C=C2C(=NO)CCC2=CC=1C1=CNN=C1C1=CC=NC=C1 HNYYFWGWLSEHQF-UHFFFAOYSA-N 0.000 claims 1
- BFXCZPXEDHBYBJ-UHFFFAOYSA-N N-[5-[1-(1-methylpiperidin-4-yl)-3-pyridin-4-ylpyrazol-4-yl]-3H-isoindol-1-yl]hydroxylamine Chemical compound C1CN(C)CCC1N1N=C(C=2C=CN=CC=2)C(C=2C=C3CNC(/C3=CC=2)=N\O)=C1 BFXCZPXEDHBYBJ-UHFFFAOYSA-N 0.000 claims 1
- 108010025020 Nerve Growth Factor Proteins 0.000 claims 1
- 102000007072 Nerve Growth Factors Human genes 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 201000010208 Seminoma Diseases 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 230000006044 T cell activation Effects 0.000 claims 1
- 208000024313 Testicular Neoplasms Diseases 0.000 claims 1
- 206010057644 Testis cancer Diseases 0.000 claims 1
- 108090000190 Thrombin Proteins 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 206010053613 Type IV hypersensitivity reaction Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 208000009956 adenocarcinoma Diseases 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 230000000172 allergic effect Effects 0.000 claims 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 1
- 230000003110 anti-inflammatory effect Effects 0.000 claims 1
- 230000001028 anti-proliverative effect Effects 0.000 claims 1
- 230000000840 anti-viral effect Effects 0.000 claims 1
- 208000010668 atopic eczema Diseases 0.000 claims 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 claims 1
- 201000009036 biliary tract cancer Diseases 0.000 claims 1
- 208000020790 biliary tract neoplasm Diseases 0.000 claims 1
- 208000015322 bone marrow disease Diseases 0.000 claims 1
- 201000000220 brain stem cancer Diseases 0.000 claims 1
- 230000030833 cell death Effects 0.000 claims 1
- 201000007455 central nervous system cancer Diseases 0.000 claims 1
- 208000015114 central nervous system disease Diseases 0.000 claims 1
- 206010008118 cerebral infarction Diseases 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- RXOAUTDNEHGRQR-UHFFFAOYSA-N chembl524643 Chemical compound N=1N(C)C=C(C=2C=C3CNC(/C3=CC=2)=N\O)C=1C1=CC=NC=C1 RXOAUTDNEHGRQR-UHFFFAOYSA-N 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 208000010247 contact dermatitis Diseases 0.000 claims 1
- 230000001066 destructive effect Effects 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 230000003325 follicular Effects 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 229930195712 glutamate Natural products 0.000 claims 1
- 210000002768 hair cell Anatomy 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 claims 1
- 208000014951 hematologic disease Diseases 0.000 claims 1
- 208000018706 hematopoietic system disease Diseases 0.000 claims 1
- 239000005556 hormone Substances 0.000 claims 1
- 229940088597 hormone Drugs 0.000 claims 1
- 230000003463 hyperproliferative effect Effects 0.000 claims 1
- 230000007954 hypoxia Effects 0.000 claims 1
- 239000002955 immunomodulating agent Substances 0.000 claims 1
- 230000002584 immunomodulator Effects 0.000 claims 1
- 229940121354 immunomodulator Drugs 0.000 claims 1
- 208000033065 inborn errors of immunity Diseases 0.000 claims 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 210000002429 large intestine Anatomy 0.000 claims 1
- 201000011061 large intestine cancer Diseases 0.000 claims 1
- 206010023841 laryngeal neoplasm Diseases 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 210000000088 lip Anatomy 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 201000005249 lung adenocarcinoma Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- GBESZLUYUDEPLT-UHFFFAOYSA-N n-[3-[4-(1-hydroxyimino-2,3-dihydroinden-5-yl)-3-pyridin-4-ylpyrazol-1-yl]propyl]-2-methoxyacetamide Chemical compound N=1N(CCCNC(=O)COC)C=C(C=2C=C3CCC(C3=CC=2)=NO)C=1C1=CC=NC=C1 GBESZLUYUDEPLT-UHFFFAOYSA-N 0.000 claims 1
- UMEKRJBKRPLHKL-UHFFFAOYSA-N n-[5-(1-cyclopentyl-3-pyridin-4-ylpyrazol-4-yl)-2,3-dihydroinden-1-ylidene]hydroxylamine Chemical compound C=1C=C2C(=NO)CCC2=CC=1C1=CN(C2CCCC2)N=C1C1=CC=NC=C1 UMEKRJBKRPLHKL-UHFFFAOYSA-N 0.000 claims 1
- ZDPNNLPNJKVPAJ-UHFFFAOYSA-N n-[5-(1-methyl-3-pyridin-4-ylpyrazol-4-yl)-1-benzofuran-3-ylidene]hydroxylamine Chemical compound N=1N(C)C=C(C=2C=C3C(=NO)COC3=CC=2)C=1C1=CC=NC=C1 ZDPNNLPNJKVPAJ-UHFFFAOYSA-N 0.000 claims 1
- PALWZOUPWYHIBZ-UHFFFAOYSA-N n-[5-(1-methyl-3-pyridin-4-ylpyrazol-4-yl)-2,3-dihydrochromen-4-ylidene]hydroxylamine Chemical compound N=1N(C)C=C(C=2C=3C(=NO)CCOC=3C=CC=2)C=1C1=CC=NC=C1 PALWZOUPWYHIBZ-UHFFFAOYSA-N 0.000 claims 1
- QULKREMAADOCHU-UHFFFAOYSA-N n-[5-(1-methyl-3-pyridin-4-ylpyrazol-4-yl)-2,3-dihydroinden-1-ylidene]hydroxylamine Chemical compound N=1N(C)C=C(C=2C=C3CCC(C3=CC=2)=NO)C=1C1=CC=NC=C1 QULKREMAADOCHU-UHFFFAOYSA-N 0.000 claims 1
- KWEFZSZCLBHIEQ-UHFFFAOYSA-N n-[5-(1-piperidin-4-yl-3-pyridin-4-ylpyrazol-4-yl)-2,3-dihydroinden-1-ylidene]hydroxylamine Chemical compound C=1C=C2C(=NO)CCC2=CC=1C1=CN(C2CCNCC2)N=C1C1=CC=NC=C1 KWEFZSZCLBHIEQ-UHFFFAOYSA-N 0.000 claims 1
- BHLMLSGRHJUIKL-UHFFFAOYSA-N n-[5-(2-pyridin-4-ylpyrazolo[1,5-a]pyrimidin-3-yl)-2,3-dihydroinden-1-ylidene]hydroxylamine Chemical compound C=1C=C2C(=NO)CCC2=CC=1C(=C1N=CC=CN1N=1)C=1C1=CC=NC=C1 BHLMLSGRHJUIKL-UHFFFAOYSA-N 0.000 claims 1
- DFDQKBZNHIAFHM-UHFFFAOYSA-N n-[5-(3-pyridin-4-yl-1-pyrrolidin-3-ylpyrazol-4-yl)-2,3-dihydroinden-1-ylidene]hydroxylamine Chemical compound C=1C=C2C(=NO)CCC2=CC=1C1=CN(C2CNCC2)N=C1C1=CC=NC=C1 DFDQKBZNHIAFHM-UHFFFAOYSA-N 0.000 claims 1
- OJMSXFJCMHLRGA-UHFFFAOYSA-N n-[5-[1-(2-aminoethyl)-3-pyridin-4-ylpyrazol-4-yl]-2,3-dihydroinden-1-ylidene]hydroxylamine Chemical compound N=1N(CCN)C=C(C=2C=C3CCC(C3=CC=2)=NO)C=1C1=CC=NC=C1 OJMSXFJCMHLRGA-UHFFFAOYSA-N 0.000 claims 1
- DTGWIQVKISSKJV-UHFFFAOYSA-N n-[5-[1-(2-piperidin-1-ylethyl)-3-pyridin-4-ylpyrazol-4-yl]-2,3-dihydroinden-1-ylidene]hydroxylamine Chemical compound C=1C=C2C(=NO)CCC2=CC=1C(C(=N1)C=2C=CN=CC=2)=CN1CCN1CCCCC1 DTGWIQVKISSKJV-UHFFFAOYSA-N 0.000 claims 1
- XBYGGIAFXHDSJP-UHFFFAOYSA-N n-[5-[1-(3-aminopropyl)-3-pyridin-4-ylpyrazol-4-yl]-2,3-dihydroinden-1-ylidene]hydroxylamine Chemical compound N=1N(CCCN)C=C(C=2C=C3CCC(C3=CC=2)=NO)C=1C1=CC=NC=C1 XBYGGIAFXHDSJP-UHFFFAOYSA-N 0.000 claims 1
- RGMKIWCFVYETDM-UHFFFAOYSA-N n-[5-[1-(4-aminobutyl)-3-pyridin-4-ylpyrazol-4-yl]-2,3-dihydroinden-1-ylidene]hydroxylamine Chemical compound N=1N(CCCCN)C=C(C=2C=C3CCC(C3=CC=2)=NO)C=1C1=CC=NC=C1 RGMKIWCFVYETDM-UHFFFAOYSA-N 0.000 claims 1
- QPROAMYIMIWMOV-UHFFFAOYSA-N n-[5-[1-(4-methylpiperidin-1-yl)-3-pyridin-4-ylpyrazol-4-yl]-2,3-dihydroinden-1-ylidene]hydroxylamine Chemical compound C1CC(C)CCN1N1N=C(C=2C=CN=CC=2)C(C=2C=C3CCC(C3=CC=2)=NO)=C1 QPROAMYIMIWMOV-UHFFFAOYSA-N 0.000 claims 1
- RZCDDUDKDKUXLC-UHFFFAOYSA-N n-[5-[1-(oxan-4-yl)-3-pyridin-4-ylpyrazol-4-yl]-2,3-dihydroinden-1-ylidene]hydroxylamine Chemical compound C=1C=C2C(=NO)CCC2=CC=1C1=CN(C2CCOCC2)N=C1C1=CC=NC=C1 RZCDDUDKDKUXLC-UHFFFAOYSA-N 0.000 claims 1
- NOBRYXWIIOWOPC-QGZVFWFLSA-N n-[5-[1-[(3r)-oxolan-3-yl]-3-pyridin-4-ylpyrazol-4-yl]-2,3-dihydroinden-1-ylidene]hydroxylamine Chemical compound C=1C=C2C(=NO)CCC2=CC=1C1=CN([C@H]2COCC2)N=C1C1=CC=NC=C1 NOBRYXWIIOWOPC-QGZVFWFLSA-N 0.000 claims 1
- AVUPTZCSKVHLFN-UHFFFAOYSA-N n-[5-[1-[2-(4-methylpiperazin-1-yl)ethyl]-3-pyridin-4-ylpyrazol-4-yl]-2,3-dihydroinden-1-ylidene]hydroxylamine Chemical compound C1CN(C)CCN1CCN1N=C(C=2C=CN=CC=2)C(C=2C=C3CCC(C3=CC=2)=NO)=C1 AVUPTZCSKVHLFN-UHFFFAOYSA-N 0.000 claims 1
- BNZFFQFIDFWDFA-UHFFFAOYSA-N n-[5-[1-[3-(aminomethyl)pyridin-2-yl]-3-pyridin-4-ylpyrazol-4-yl]-2,3-dihydroinden-1-ylidene]hydroxylamine Chemical compound NCC1=CC=CN=C1N1N=C(C=2C=CN=CC=2)C(C=2C=C3CCC(C3=CC=2)=NO)=C1 BNZFFQFIDFWDFA-UHFFFAOYSA-N 0.000 claims 1
- CYJGATFIVAHKTM-UHFFFAOYSA-N n-[5-[1-[4-(aminomethyl)phenyl]-3-pyridin-4-ylpyrazol-4-yl]-2,3-dihydroinden-1-ylidene]hydroxylamine Chemical compound C1=CC(CN)=CC=C1N1N=C(C=2C=CN=CC=2)C(C=2C=C3CCC(C3=CC=2)=NO)=C1 CYJGATFIVAHKTM-UHFFFAOYSA-N 0.000 claims 1
- ZNRRHRJCCXLLCS-UHFFFAOYSA-N n-[5-[1-[5-(aminomethyl)pyridin-2-yl]-3-pyridin-4-ylpyrazol-4-yl]-2,3-dihydroinden-1-ylidene]hydroxylamine Chemical compound N1=CC(CN)=CC=C1N1N=C(C=2C=CN=CC=2)C(C=2C=C3CCC(C3=CC=2)=NO)=C1 ZNRRHRJCCXLLCS-UHFFFAOYSA-N 0.000 claims 1
- WWZAMNZDVNQWRK-UHFFFAOYSA-N n-[6-[4-(1-hydroxyimino-2,3-dihydroinden-5-yl)-3-pyridin-4-ylpyrazol-1-yl]pyridin-3-yl]acetamide Chemical compound N1=CC(NC(=O)C)=CC=C1N1N=C(C=2C=CN=CC=2)C(C=2C=C3CCC(C3=CC=2)=NO)=C1 WWZAMNZDVNQWRK-UHFFFAOYSA-N 0.000 claims 1
- 201000001119 neuropathy Diseases 0.000 claims 1
- 230000007823 neuropathy Effects 0.000 claims 1
- 231100000189 neurotoxic Toxicity 0.000 claims 1
- 230000002887 neurotoxic effect Effects 0.000 claims 1
- 239000003900 neurotrophic factor Substances 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 150000002923 oximes Chemical class 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 201000010198 papillary carcinoma Diseases 0.000 claims 1
- 230000001575 pathological effect Effects 0.000 claims 1
- 208000033808 peripheral neuropathy Diseases 0.000 claims 1
- 210000003800 pharynx Anatomy 0.000 claims 1
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 claims 1
- XKJCHHZQLQNZHY-UHFFFAOYSA-N phthalimide Chemical compound C1=CC=C2C(=O)NC(=O)C2=C1 XKJCHHZQLQNZHY-UHFFFAOYSA-N 0.000 claims 1
- 208000028529 primary immunodeficiency disease Diseases 0.000 claims 1
- 230000002062 proliferating effect Effects 0.000 claims 1
- 125000004307 pyrazin-2-yl group Chemical group [H]C1=C([H])N=C(*)C([H])=N1 0.000 claims 1
- 125000002206 pyridazin-3-yl group Chemical group [H]C1=C([H])C([H])=C(*)N=N1 0.000 claims 1
- 125000004940 pyridazin-4-yl group Chemical group N1=NC=C(C=C1)* 0.000 claims 1
- 125000004941 pyridazin-5-yl group Chemical group N1=NC=CC(=C1)* 0.000 claims 1
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 claims 1
- 125000004528 pyrimidin-5-yl group Chemical group N1=CN=CC(=C1)* 0.000 claims 1
- 125000004943 pyrimidin-6-yl group Chemical group N1=CN=CC=C1* 0.000 claims 1
- 102000009929 raf Kinases Human genes 0.000 claims 1
- 108010077182 raf Kinases Proteins 0.000 claims 1
- 210000000664 rectum Anatomy 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 229920006395 saturated elastomer Polymers 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 208000000649 small cell carcinoma Diseases 0.000 claims 1
- 210000000813 small intestine Anatomy 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 125000003107 substituted aryl group Chemical group 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- GEQCVKWGYURITF-UHFFFAOYSA-N tert-butyl n-[5-[1-(2-hydroxyethyl)-3-pyridin-4-ylpyrazol-4-yl]-2,3-dihydro-1h-inden-1-yl]carbamate Chemical compound C=1C=C2C(NC(=O)OC(C)(C)C)CCC2=CC=1C1=CN(CCO)N=C1C1=CC=NC=C1 GEQCVKWGYURITF-UHFFFAOYSA-N 0.000 claims 1
- 201000003120 testicular cancer Diseases 0.000 claims 1
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 claims 1
- 229960004072 thrombin Drugs 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
- 210000002105 tongue Anatomy 0.000 claims 1
- 238000002054 transplantation Methods 0.000 claims 1
- 230000008733 trauma Effects 0.000 claims 1
- 125000004665 trialkylsilyl group Chemical group 0.000 claims 1
- 125000005039 triarylmethyl group Chemical group 0.000 claims 1
- 230000005951 type IV hypersensitivity Effects 0.000 claims 1
- 208000027930 type IV hypersensitivity disease Diseases 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 239000003981 vehicle Substances 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
- 0 *C1C(*)=C(c2c(*)[n](*)nc2*)C(*)=C(CN2*)[C@]1C2=N* Chemical compound *C1C(*)=C(c2c(*)[n](*)nc2*)C(*)=C(CN2*)[C@]1C2=N* 0.000 description 2
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US65005005P | 2005-02-04 | 2005-02-04 | |
| PCT/US2006/003654 WO2006084015A2 (en) | 2005-02-04 | 2006-02-02 | Raf inhibitor compounds and methods |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008530011A JP2008530011A (ja) | 2008-08-07 |
| JP2008530011A5 true JP2008530011A5 (enExample) | 2009-02-26 |
Family
ID=36571626
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007554205A Pending JP2008530011A (ja) | 2005-02-04 | 2006-02-02 | Ｒａｆインヒビター化合物および方法 |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US7491829B2 (enExample) |
| EP (1) | EP1846391A2 (enExample) |
| JP (1) | JP2008530011A (enExample) |
| KR (1) | KR20070107104A (enExample) |
| CN (1) | CN101282960A (enExample) |
| AR (1) | AR053014A1 (enExample) |
| AU (1) | AU2006210626A1 (enExample) |
| BR (1) | BRPI0607346A2 (enExample) |
| CA (1) | CA2596973A1 (enExample) |
| CR (1) | CR9365A (enExample) |
| IL (1) | IL185024A0 (enExample) |
| MA (1) | MA29310B1 (enExample) |
| MX (1) | MX2007009405A (enExample) |
| NO (1) | NO20074473L (enExample) |
| RU (1) | RU2007133111A (enExample) |
| TW (1) | TW200639163A (enExample) |
| WO (1) | WO2006084015A2 (enExample) |
| ZA (1) | ZA200707289B (enExample) |
Families Citing this family (91)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103739595A (zh) | 2006-10-02 | 2014-04-23 | Irm责任有限公司 | 作为蛋白激酶抑制剂的化合物和组合物 |
| EP2114895A4 (en) * | 2006-10-17 | 2011-06-22 | Stiefel Laboratories | TALARAZOLMETABOLITEN |
| US20090082354A1 (en) * | 2007-09-20 | 2009-03-26 | Wyeth | Pyrazolo[5, 1-c] [1,2,4] triazines, methods for preparation and use thereof |
| US20110003859A1 (en) * | 2008-02-29 | 2011-01-06 | Array Biopharma Inc. | N- (6-aminopyridin-3-yl) -3- (sulfonamido) benzamide derivatives as b-raf inhibitors for the treatment of cancer |
| WO2009111260A1 (en) * | 2008-02-29 | 2009-09-11 | Wyeth | Phenylsulfonamide-substituted, pyrazolo[1, 5-a]pyrimidines, methods for preparation and uses thereof |
| MX2010009410A (es) * | 2008-02-29 | 2010-11-30 | Array Biopharma Inc | Compuestos del inhibidor de raf y métodos de uso de los mismos. |
| WO2009108827A1 (en) * | 2008-02-29 | 2009-09-03 | Wyeth | Fused tricyclic pyrazolo[1, 5-a]pyrimidines, methods for preparation and uses thereof |
| JP2011513329A (ja) * | 2008-02-29 | 2011-04-28 | アレイ バイオファーマ、インコーポレイテッド | ＲＡＦ阻害化合物として使用されるイミダゾ［４，５−ｂ］ピリジン誘導体 |
| CL2009000448A1 (es) * | 2008-02-29 | 2009-11-27 | Genentech Inc | Compuestos derivados de 3-sulfonilamino-n-(1h-pirazolo-[3,4-b]piridin-5il)benzamida; procesos de preparacion; compuestos intermediarios; composicion farmaceutica; y uso para el tratamiento del cancer, tal como sarcoma, carcinoma, adenoma, entre otros. |
| JP2009286773A (ja) * | 2008-03-14 | 2009-12-10 | Bayer Cropscience Ag | 殺虫性縮環式アリール類 |
| MX2010012703A (es) | 2008-05-21 | 2010-12-21 | Ariad Pharma Inc | Derivados fosforosos como inhibidores de cinasa. |
| US9273077B2 (en) | 2008-05-21 | 2016-03-01 | Ariad Pharmaceuticals, Inc. | Phosphorus derivatives as kinase inhibitors |
| CA2744563A1 (en) * | 2008-12-12 | 2010-06-17 | Ariad Pharmaceuticals, Inc. | Azaindole derivatives as kinase inhibitors |
| WO2010144909A1 (en) | 2009-06-12 | 2010-12-16 | Novartis Ag | Fused heterocyclic compounds and their uses |
| SG178561A1 (en) | 2009-08-28 | 2012-03-29 | Array Biopharma Inc | 1h-pyrazolo [ 3, 4-b] pyridine compounds for inhibiting raf kinase |
| SG178900A1 (en) * | 2009-08-28 | 2012-04-27 | Genentech Inc | Raf inhibitor compounds and methods of use thereof |
| CN102712646A (zh) | 2009-08-28 | 2012-10-03 | 阵列生物制药公司 | Raf抑制剂化合物及其使用方法 |
| JP2013503189A (ja) | 2009-08-28 | 2013-01-31 | アレイ バイオファーマ、インコーポレイテッド | Ｒａｆ阻害化合物およびその使用方法 |
| EP2493865A2 (en) | 2009-08-28 | 2012-09-05 | Array Biopharma, Inc. | Raf inhibitor compounds and methods of use thereof |
| WO2011025951A1 (en) | 2009-08-28 | 2011-03-03 | Array Biopharma Inc. | Raf inhibitor compounds and methods of use thereof |
| DK2493871T3 (da) * | 2009-10-30 | 2014-11-10 | Prestwick Chemical Sas | Nye oximderivater samt deres anvendelse som allosteriske modulatorer af metabotropiske glutamatreceptorer |
| US9180127B2 (en) | 2009-12-29 | 2015-11-10 | Dana-Farber Cancer Institute, Inc. | Type II Raf kinase inhibitors |
| PH12012501361A1 (en) | 2009-12-31 | 2012-10-22 | Centro Nac De Investigaciones Oncologicas Cnio | Tricyclic compounds for use as kinase inhibitors |
| US20120122928A1 (en) | 2010-08-11 | 2012-05-17 | Bayer Cropscience Ag | Heteroarylpiperidine and -Piperazine Derivatives as Fungicides |
| EP2423210A1 (de) | 2010-08-25 | 2012-02-29 | Bayer CropScience AG | Heteroarylpiperidin- und -piperazinderivate als Fungizide |
| US8759527B2 (en) | 2010-08-25 | 2014-06-24 | Bayer Cropscience Ag | Heteroarylpiperidine and -piperazine derivatives as fungicides |
| BR112013010497B1 (pt) | 2010-10-27 | 2018-07-17 | Bayer Intellectual Property Gmbh | derivados de heteroaril - piperidina e - piperazina enquanto fungicidas, composição os compreendendo, bem como processo para a produção de composições para controle de fungos fitopatogênicos nocivos e método para controle de fungos fitopatogênicos nocivos |
| CA2824028A1 (en) | 2011-01-06 | 2012-07-12 | Beta Pharma Canada Inc. | Novel ureas for the treatment and prevention of cancer |
| WO2012098387A1 (en) | 2011-01-18 | 2012-07-26 | Centro Nacional De Investigaciones Oncológicas (Cnio) | 6, 7-ring-fused triazolo [4, 3 - b] pyridazine derivatives as pim inhibitors |
| BR112013019667B1 (pt) | 2011-02-01 | 2019-07-02 | Bayer Intellectual Property Gmbh | Compostos derivados de heteroaril-piperidina e -piperazina, seus usos, composição, processos de produção de compostos e de composições, método para o controle de fungos fitopatogênicos prejudiciais |
| WO2012145503A1 (en) | 2011-04-21 | 2012-10-26 | Novartis Ag | Pharmaceutical combinations |
| BR112013027734A2 (pt) | 2011-05-04 | 2017-08-08 | Ariad Pharma Inc | compostos para a inibição de proliferação celular em cânceres impulsionados pelo egfr, método e composição farmacêutica |
| EA026924B1 (ru) | 2011-08-01 | 2017-05-31 | Дженентек, Инк. | Способы лечения рака с использованием антагонистов, связывающихся с осью pd-1, и ингибиторов mek |
| US20130078252A1 (en) | 2011-09-19 | 2013-03-28 | Genentech, Inc. | Combination treatments comprising c-met antagonists and b-raf antagonists |
| CA2856291C (en) | 2011-11-17 | 2020-08-11 | Dana-Farber Cancer Institute, Inc. | Inhibitors of c-jun-n-terminal kinase (jnk) |
| US9408885B2 (en) | 2011-12-01 | 2016-08-09 | Vib Vzw | Combinations of therapeutic agents for treating melanoma |
| ES2647442T3 (es) | 2011-12-27 | 2017-12-21 | Bayer Intellectual Property Gmbh | Compuestos intermedios para la preparación de derivados de heteroarilpiperidina y de heteroarilpiperazina como fungicidas |
| HUE029656T2 (en) | 2011-12-31 | 2017-03-28 | Beigene Ltd | Condensed tricyclic compounds as RAF kinase inhibitors |
| AU2013204563B2 (en) | 2012-05-05 | 2016-05-19 | Takeda Pharmaceutical Company Limited | Compounds for inhibiting cell proliferation in EGFR-driven cancers |
| SI2884979T1 (sl) | 2012-08-17 | 2019-10-30 | Hoffmann La Roche | Kombinirana zdravljenja melanoma, ki vključujejo dajanje kobimetiniba in vemurafeniba |
| EP2909194A1 (en) | 2012-10-18 | 2015-08-26 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 7 (cdk7) |
| WO2014063054A1 (en) | 2012-10-19 | 2014-04-24 | Dana-Farber Cancer Institute, Inc. | Bone marrow on x chromosome kinase (bmx) inhibitors and uses thereof |
| US9758522B2 (en) | 2012-10-19 | 2017-09-12 | Dana-Farber Cancer Institute, Inc. | Hydrophobically tagged small molecules as inducers of protein degradation |
| EP2958592A1 (en) | 2013-02-22 | 2015-12-30 | F. Hoffmann-La Roche AG | Methods of treating cancer and preventing drug resistance |
| JO3383B1 (ar) * | 2013-03-14 | 2019-03-13 | Lilly Co Eli | مثبطات cdc7 |
| CN105339001A (zh) | 2013-03-15 | 2016-02-17 | 基因泰克公司 | 治疗癌症和预防癌症耐药性的方法 |
| US9611283B1 (en) | 2013-04-10 | 2017-04-04 | Ariad Pharmaceuticals, Inc. | Methods for inhibiting cell proliferation in ALK-driven cancers |
| WO2014206344A1 (en) | 2013-06-28 | 2014-12-31 | Beigene, Ltd. | Fused tricyclic amide compounds as multiple kinase inhibitors |
| JP6623353B2 (ja) | 2013-09-13 | 2019-12-25 | ベイジーン スウィッツァーランド ゲーエムベーハー | 抗ｐｄ−１抗体並びにその治療及び診断のための使用 |
| WO2015041533A1 (en) | 2013-09-20 | 2015-03-26 | Stichting Het Nederlands Kanker Instituut | Rock in combination with mapk-pathway |
| WO2015041534A1 (en) | 2013-09-20 | 2015-03-26 | Stichting Het Nederlands Kanker Instituut | P90rsk in combination with raf/erk/mek |
| AU2014337122B2 (en) | 2013-10-18 | 2019-01-03 | Dana-Farber Cancer Institute, Inc. | Heteroaromatic compounds useful for the treatment of proliferative diseases |
| US10047070B2 (en) | 2013-10-18 | 2018-08-14 | Dana-Farber Cancer Institute, Inc. | Polycyclic inhibitors of cyclin-dependent kinase 7 (CDK7) |
| BR112016021383A2 (pt) | 2014-03-24 | 2017-10-03 | Genentech Inc | Método para identificar um paciente com câncer que é susceptível ou menos susceptível a responder ao tratamento com um antagonista de cmet, método para identificar um paciente apresentando câncer previamente tratado, método para determinar a expressão do biomarcador hgf, antagonista anti-c-met e seu uso, kit de diagnóstico e seu método de preparo |
| WO2015156674A2 (en) | 2014-04-10 | 2015-10-15 | Stichting Het Nederlands Kanker Instituut | Method for treating cancer |
| US9862688B2 (en) | 2014-04-23 | 2018-01-09 | Dana-Farber Cancer Institute, Inc. | Hydrophobically tagged janus kinase inhibitors and uses thereof |
| WO2015164614A1 (en) | 2014-04-23 | 2015-10-29 | Dana-Farber Cancer Institute, Inc. | Janus kinase inhibitors and uses thereof |
| WO2015178770A1 (en) | 2014-05-19 | 2015-11-26 | Stichting Het Nederlands Kanker Instituut | Compositions for cancer treatment |
| CN107073121A (zh) | 2014-06-13 | 2017-08-18 | 基因泰克公司 | 治疗及预防癌症药物抗性的方法 |
| WO2015196072A2 (en) | 2014-06-19 | 2015-12-23 | Whitehead Institute For Biomedical Research | Uses of kinase inhibitors for inducing and maintaining pluripotency |
| KR102003754B1 (ko) | 2014-07-03 | 2019-07-25 | 베이진 엘티디 | Pd-l1 항체와 이를 이용한 치료 및 진단 |
| EP3563870A1 (en) | 2014-07-15 | 2019-11-06 | F. Hoffmann-La Roche AG | Methods of treating cancer using pd-1 axis binding antagonists and mek inhibitors |
| JP6986965B2 (ja) | 2014-07-22 | 2021-12-22 | アポロミクス インコーポレイテッド | 抗ｐｄ−１抗体 |
| WO2016022630A1 (en) | 2014-08-05 | 2016-02-11 | Jiping Zha | Anti-pd-l1 antibodies |
| EP3236959B1 (en) | 2014-12-23 | 2025-09-24 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 7 (cdk7) |
| AU2016243529B2 (en) | 2015-03-27 | 2021-03-25 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinases |
| CA2981746C (en) | 2015-04-15 | 2023-08-01 | Beigene, Ltd. | Maleate salts of a b-raf kinase inhibitor, crystalline forms, methods of preparation, and uses therefore |
| US10702527B2 (en) | 2015-06-12 | 2020-07-07 | Dana-Farber Cancer Institute, Inc. | Combination therapy of transcription inhibitors and kinase inhibitors |
| EP4019515A1 (en) | 2015-09-09 | 2022-06-29 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinases |
| CN121154828A (zh) | 2015-11-19 | 2025-12-19 | 豪夫迈·罗氏有限公司 | 使用b-raf抑制剂和免疫检查点抑制剂治疗癌症的方法 |
| NZ749997A (en) | 2016-07-05 | 2022-11-25 | Beigene Ltd | Combination of a pd-l antagonist and a raf inhibitor for treating cancer |
| EP3500299B1 (en) | 2016-08-19 | 2023-12-13 | BeiGene Switzerland GmbH | Combination of zanubrutinib with an anti-cd20 or an anti-pd-1 antibody for use in treating cancer |
| CN118834201A (zh) | 2016-12-01 | 2024-10-25 | 阿尔维纳斯运营股份有限公司 | 作为雌激素受体降解剂的四氢萘和四氢异喹啉衍生物 |
| KR102839545B1 (ko) * | 2016-12-23 | 2025-07-29 | 아비나스 오퍼레이션스, 인코포레이티드 | 급속 진행성 섬유육종 폴리펩티드의 표적화 분해를 위한 화합물 및 방법 |
| US11173211B2 (en) | 2016-12-23 | 2021-11-16 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of rapidly accelerated Fibrosarcoma polypeptides |
| WO2018137681A1 (en) | 2017-01-25 | 2018-08-02 | Beigene, Ltd. | Crystalline forms of (s) -7- (1- (but-2-ynoyl) piperidin-4-yl) -2- (4-phenoxyphenyl) -4, 5, 6, 7-tetrahy dropyrazolo [1, 5-a] pyrimidine-3-carboxamide, preparation, and uses thereof |
| EP3579872A1 (en) | 2017-02-10 | 2019-12-18 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of cancers associated with activation of the mapk pathway |
| KR102757960B1 (ko) | 2017-06-26 | 2025-01-22 | 베이진 엘티디 | 간세포암(hepatocellular carcinoma: HCC)에 대한 면역 치료 |
| WO2019108795A1 (en) | 2017-11-29 | 2019-06-06 | Beigene Switzerland Gmbh | Treatment of indolent or aggressive b-cell lymphomas using a combination comprising btk inhibitors |
| EP3732285A1 (en) | 2017-12-28 | 2020-11-04 | Tract Pharmaceuticals, Inc. | Stem cell culture systems for columnar epithelial stem cells, and uses related thereto |
| JP7590185B2 (ja) | 2018-06-25 | 2024-11-26 | ダナ－ファーバー キャンサー インスティテュート， インコーポレイテッド | Ｔａｉｒｅファミリーキナーゼインヒビターおよびそれらの使用 |
| AU2019413694B2 (en) | 2018-12-28 | 2025-03-20 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 7 and uses thereof |
| IL290789B2 (en) | 2019-08-26 | 2025-09-01 | Arvinas Operations Inc | Methods for treating breast cancer with a history of tetrahydronaphthalene as estrogen receptor-disrupting agents |
| WO2021120890A1 (en) | 2019-12-20 | 2021-06-24 | Novartis Ag | Pyrazolyl derivatives useful as anti-cancer agents |
| US12180193B2 (en) | 2020-08-28 | 2024-12-31 | Arvinas Operations, Inc. | Accelerating fibrosarcoma protein degrading compounds and associated methods of use |
| KR20230069144A (ko) | 2020-09-14 | 2023-05-18 | 아비나스 오퍼레이션스, 인코포레이티드 | 에스트로겐 수용체의 표적화된 분해를 위한 화합물의 결정질 형태 |
| KR20230098252A (ko) * | 2020-10-30 | 2023-07-03 | 노파르티스 아게 | Kras g12c 억제제 화합물의 새로운 결정형 |
| US12371667B2 (en) | 2021-05-13 | 2025-07-29 | Washington University | Enhanced methods for inducing and maintaining naive human pluripotent stem cells |
| CN117730075A (zh) * | 2021-11-30 | 2024-03-19 | 上海和誉生物医药科技有限公司 | 一种吡唑衍生物，其制备方法和在药学上的应用 |
| WO2024022186A1 (zh) * | 2022-07-29 | 2024-02-01 | 四川科伦博泰生物医药股份有限公司 | 甲基吡唑化合物、包含其的药物组合物及其制备方法和用途 |
| EP4584258A1 (en) | 2022-09-07 | 2025-07-16 | Arvinas Operations, Inc. | Rapidly accelerated fibrosarcoma (raf) degrading compounds and associated methods of use |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1245283A (en) | 1968-10-04 | 1971-09-08 | Labaz | Pyrazole derivatives |
| JP2753659B2 (ja) | 1990-09-03 | 1998-05-20 | 株式会社大塚製薬工場 | ピラゾール誘導体 |
| US5356897A (en) | 1991-09-09 | 1994-10-18 | Fujisawa Pharmaceutical Co., Ltd. | 3-(heteroaryl)-pyrazololi[1,5-a]pyrimidines |
| JPH05125079A (ja) | 1991-11-05 | 1993-05-21 | Otsuka Pharmaceut Factory Inc | ピラゾロ［１，５−ａピリミジン誘導体 |
| EP0714898B1 (en) | 1994-06-21 | 2001-11-14 | Otsuka Pharmaceutical Factory, Inc. | PYRAZOLO [1,5-a]PYRIMIDINE DERIVATIVE |
| US5486534A (en) | 1994-07-21 | 1996-01-23 | G. D. Searle & Co. | 3,4-substituted pyrazoles for the treatment of inflammation |
| WO1997011946A1 (en) | 1995-09-28 | 1997-04-03 | Otsuka Pharmaceutical Factory, Inc. | Analgesics |
| JPH10101672A (ja) | 1996-08-06 | 1998-04-21 | Otsuka Pharmaceut Factory Inc | アデノシン増強剤 |
| JPH10101671A (ja) | 1996-08-08 | 1998-04-21 | Otsuka Pharmaceut Factory Inc | 一酸化窒素合成酵素阻害剤 |
| PL336990A1 (en) | 1997-05-22 | 2000-07-31 | Searle & Co | 3(5)-heteroaryl group substituted pyrazoles as inhibitors of kinase p 38 |
| US6514977B1 (en) | 1997-05-22 | 2003-02-04 | G.D. Searle & Company | Substituted pyrazoles as p38 kinase inhibitors |
| JP2000153671A (ja) | 1998-11-20 | 2000-06-06 | Fuji Photo Film Co Ltd | 感熱記録材料 |
| JP2002542280A (ja) | 1999-04-27 | 2002-12-10 | スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー | 新規な治療 |
| TWI271406B (en) | 1999-12-13 | 2007-01-21 | Eisai Co Ltd | Tricyclic condensed heterocyclic compounds, preparation method of the same and pharmaceuticals comprising the same |
| AU2001236720A1 (en) | 2000-02-05 | 2001-08-14 | Bemis, Guy | Compositions useful as inhibitors of erk |
| WO2001056993A2 (en) | 2000-02-05 | 2001-08-09 | Vertex Pharmaceuticals Incorporated | Pyrazole compositions useful as inhibitors of erk |
| EP1200422A2 (en) | 2000-02-05 | 2002-05-02 | Vertex Pharmaceuticals Incorporated | Pyrazole compositions useful as inhibitors of erk |
| JP2003525936A (ja) | 2000-03-06 | 2003-09-02 | スミスクライン ビーチャム パブリック リミテッド カンパニー | Ｒａｆキナーゼ阻害物質としてのイミダゾール誘導体 |
| EP1318992B1 (en) | 2000-09-21 | 2005-07-27 | Smithkline Beecham Plc | Imidazole derivatives as raf kinase inhibitors |
| HUP0303653A3 (en) | 2000-12-28 | 2006-05-29 | Ono Pharmaceutical Co | Tricyclic and heterocyclic derivative and pharmaceutical compositions containing them as the active ingredient |
| EP1361225B1 (en) | 2001-01-22 | 2007-11-07 | Sankyo Company, Limited | Compounds substituted with bicyclic amino groups |
| ES2251582T3 (es) * | 2001-03-09 | 2006-05-01 | Pfizer Products Inc. | Compuestos antiinflamatorios de bencimidazol. |
| DE60227794D1 (de) | 2001-04-26 | 2008-09-04 | Eisai R&D Man Co Ltd | Stickstoffhaltige verbindung mit kondensiertem ring und pyrazolylgruppe als substituent und medizinische zusammensetzung davon |
| GB0112348D0 (en) | 2001-05-19 | 2001-07-11 | Smithkline Beecham Plc | Compounds |
| SK287857B6 (sk) * | 2001-05-24 | 2012-01-04 | Eli Lilly And Company | Novel pyrrole derivatives as pharmaceutical agents |
| DE60238620D1 (de) | 2001-08-03 | 2011-01-27 | Vertex Pharma | Von pyrazol abgeleitete kinaseinhibitoren und deren verwendung |
| CA2456192A1 (en) | 2001-08-03 | 2003-02-13 | Qing Tang | Pyrazole-derived kinase inhibitors and uses thereof |
| GB0121490D0 (en) | 2001-09-05 | 2001-10-24 | Smithkline Beecham Plc | Ciompounds |
| GB0121494D0 (en) | 2001-09-05 | 2001-10-24 | Smithkline Beecham Plc | Compounds |
| US6897208B2 (en) | 2001-10-26 | 2005-05-24 | Aventis Pharmaceuticals Inc. | Benzimidazoles |
| US20040010027A1 (en) * | 2001-12-17 | 2004-01-15 | Pharmacia & Upjohn Spa | Hydroxphenyl-pyrazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical comositions comprising them |
| JP4286146B2 (ja) * | 2001-12-18 | 2009-06-24 | メルク エンド カムパニー インコーポレーテッド | メタボトロピックグルタミン酸受容体−５のヘテロアリール置換ピラゾール系調節剤 |
| JP4399265B2 (ja) * | 2001-12-21 | 2010-01-13 | ヴァーナリス（ケンブリッジ）リミテッド | ３，４−ジアリールピラゾール、および癌の治療におけるそれらの使用 |
| ES2287476T3 (es) | 2002-05-10 | 2007-12-16 | Smithkline Beecham Corporation | Pirazolopirimidinas sustituidas. |
| GB0217786D0 (en) | 2002-07-31 | 2002-09-11 | Glaxo Group Ltd | Compounds |
| WO2004013135A1 (en) | 2002-07-31 | 2004-02-12 | Smithkline Beecham Corporation | 2-phenylpyridin-4-yl derivatives as alk5 inhibitors |
| DE60309342T2 (de) | 2002-08-09 | 2007-05-16 | Eli Lilly And Co., Indianapolis | Benzimidazole und benzothiazole als inhibitoren der map-kinase |
| AU2003273295B2 (en) | 2002-09-09 | 2007-03-22 | Amgen Inc. | 1, 4, 5-substituted 1, 2-dihydro-pyrazol-3-one derivatives as TNF-alpha and interleukin lowering agents for the treatment of inflammation |
| EP1543001B1 (en) * | 2002-09-17 | 2007-08-15 | Eli Lilly And Company | Pyrazolopyridine derivatives as tgf beta signal transduction inhibitors for the treatment of cancer |
| PL375979A1 (en) | 2002-09-18 | 2005-12-12 | Pfizer Products Inc. | Pyrazole derivatives as transforming growth factor (tgf) inhibitors |
| WO2004026302A1 (en) | 2002-09-19 | 2004-04-01 | Eli Lilly And Company | Methods of inhibiting tgf beta with substituted pyrazoles |
| WO2004050659A1 (en) * | 2002-11-27 | 2004-06-17 | Eli Lilly And Company | Novel compounds as pharmaceutical agents |
| US7176210B2 (en) | 2003-02-10 | 2007-02-13 | Pfizer Inc. | Cannabinoid receptor ligands and uses thereof |
| CL2004000234A1 (es) | 2003-02-12 | 2005-04-15 | Biogen Idec Inc | Compuestos derivados 3-(piridin-2-il)-4-heteroaril-pirazol sustituidos, antagonistas de aik5 y/o aik4; composicion farmaceutica y uso del compuesto en el tratamiento de desordenes fibroticos como esclerodermia, lupus nefritico, cicatrizacion de herid |
| GB0313915D0 (en) * | 2003-06-16 | 2003-07-23 | Smithkline Beecham Corp | Compounds |
-
2006
- 2006-01-27 TW TW095103640A patent/TW200639163A/zh unknown
- 2006-02-02 CA CA002596973A patent/CA2596973A1/en not_active Abandoned
- 2006-02-02 US US11/345,828 patent/US7491829B2/en not_active Expired - Fee Related
- 2006-02-02 EP EP06734199A patent/EP1846391A2/en not_active Withdrawn
- 2006-02-02 BR BRPI0607346-8A patent/BRPI0607346A2/pt not_active IP Right Cessation
- 2006-02-02 WO PCT/US2006/003654 patent/WO2006084015A2/en not_active Ceased
- 2006-02-02 AU AU2006210626A patent/AU2006210626A1/en not_active Abandoned
- 2006-02-02 JP JP2007554205A patent/JP2008530011A/ja active Pending
- 2006-02-02 RU RU2007133111/04A patent/RU2007133111A/ru not_active Application Discontinuation
- 2006-02-02 KR KR1020077020119A patent/KR20070107104A/ko not_active Withdrawn
- 2006-02-02 MX MX2007009405A patent/MX2007009405A/es not_active Application Discontinuation
- 2006-02-02 CN CNA2006800109351A patent/CN101282960A/zh active Pending
- 2006-02-03 AR ARP060100401A patent/AR053014A1/es not_active Application Discontinuation
-
2007
- 2007-08-02 IL IL185024A patent/IL185024A0/en unknown
- 2007-08-17 MA MA30151A patent/MA29310B1/fr unknown
- 2007-08-28 ZA ZA200707289A patent/ZA200707289B/xx unknown
- 2007-09-03 NO NO20074473A patent/NO20074473L/no not_active Application Discontinuation
- 2007-09-04 CR CR9365A patent/CR9365A/es not_active Application Discontinuation
-
2008
- 2008-12-31 US US12/347,412 patent/US20090176809A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008530011A5 (enExample) | ||
| RU2007133111A (ru) | Соединения, ингибирующие raf, и способы | |
| US20220251041A1 (en) | 1-cyano-pyrrolidine compounds as usp30 inhibitors | |
| US12202826B2 (en) | N-pyridinyl acetamide derivatives as inhibitors of the Wnt signaling pathway | |
| US10369153B2 (en) | Pyrrolopyrimidine compounds and uses thereof | |
| AU2001295026B2 (en) | Inhibitors of glycogen synthase kinase 3 | |
| JP4814783B2 (ja) | ピラゾロピリジン誘導体 | |
| TWI583681B (zh) | 胺基嘧啶基化合物 | |
| US7425557B2 (en) | Inhibitors of glycogen synthase kinase 3 | |
| US7037918B2 (en) | Inhibitors of glycogen synthase kinase 3 | |
| US20060063789A1 (en) | Aminobenzamide derivatives as glycogen synthase kinase 3 beta inhibitors | |
| JP7517992B2 (ja) | 化合物及びその使用 | |
| US20130310395A1 (en) | Compounds and compositions for inhibiting the activity of abl1, abl2 and bcr-abl1 | |
| US20220017520A1 (en) | Macrocyclic compound as cdk inhibitor, preparation method therefor, and use thereof in medicine | |
| AU2002363177A1 (en) | Aminobenzamide derivatives as glycogen synthase kinase 3Beta inhibitors | |
| US20140288044A1 (en) | Compositions and therapeutic uses of ikk-related kinase epsilon and tankbinding kinase 1 inhibitors | |
| CN105764514A (zh) | 作为tam族激酶抑制剂的氨基吡啶衍生物 | |
| US20230069174A1 (en) | Nitrogen-containing heterocyclic autotaxin inhibitor, and composition containing same and use thereof | |
| KR20050033660A (ko) | Ｎ-바이아릴메틸 아미노사이클로알칸카복스아미드 유도체 | |
| CA2999935A1 (en) | New imidazo[4,5-b]pyridine derivatives as dual dyrk1/clk1 inhibitors | |
| JP6176244B2 (ja) | 芳香族複素環誘導体及び医薬 | |
| US20220218688A1 (en) | Pyridylpyridone compounds | |
| WO2017068064A1 (en) | Pyridone derivatives and their use as kinase inhibitors | |
| WO2025113806A1 (en) | Thiophene and thiazole derivatives as wip1 inhibitors | |
| HK1138844A (en) | 8-oxy-quinoline derivatives as bradykinin b2 receptor modulators |